^
No biomarker
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: A1 - Approval
No biomarker
Waldenstrom Macroglobulinemia
rituximab + ibrutinib
Sensitive: A1 - Approval
No biomarker
Waldenstrom Macroglobulinemia
ibrutinib
Sensitive: A1 - Approval
No biomarker
Waldenstrom Macroglobulinemia
acalabrutinib
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
fludarabine oral
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
rituximab
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
cladribine
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
rituximab + bortezomib
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
everolimus
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
bortezomib
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
ofatumumab
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
rituximab + carfilzomib + dexamethasone
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
R-CHOP
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
IRd
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
FCR
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
bortezomib + dexamethasone
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
bendamustine
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
BDR
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
BR
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
CaRD
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
RCD
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
RCP
Sensitive: A2 - Guideline
No biomarker
Waldenstrom Macroglobulinemia
I-131-CLR1404
Sensitive: B - Late Trials
No biomarker
Lymphoplasmacytic Lymphoma
I-131-CLR1404
Sensitive: B - Late Trials
MYD88 L265P
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: B - Late Trials
MYD88 mutation
Waldenstrom Macroglobulinemia
ibrutinib
Sensitive: C2 – Inclusion Criteria
CXCR4 mutation
Waldenstrom Macroglobulinemia
ibrutinib
Sensitive: C2 – Inclusion Criteria
CXCR4 mutation
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: C2 – Inclusion Criteria
MYD88 L265P
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: C2 – Inclusion Criteria
CXCR4 mutation
Waldenstrom Macroglobulinemia
venetoclax
Sensitive: C2 – Inclusion Criteria
MYD88 mutation + CXCR4 mutation
Waldenstrom Macroglobulinemia
ibrutinib
Sensitive: C2 – Inclusion Criteria
CXCR4 mutation
Waldenstrom Macroglobulinemia
BDR
Sensitive: C3 – Early Trials
CXCR4 mutation
Waldenstrom Macroglobulinemia
rituximab + carfilzomib
Sensitive: C3 – Early Trials
CXCR4 G336X
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: C3 – Early Trials
CXCR4 S338X
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: C3 – Early Trials
CXCR4 H350fs*
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: C3 – Early Trials
CXCR4 S338X + TP53 R196X
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: C3 – Early Trials
CXCR4 K327fs*
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: C3 – Early Trials
CXCR4 R338X
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: C3 – Early Trials
CXCR4 T318fs*
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: C3 – Early Trials
CXCR4 L326fs*
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: C3 – Early Trials
CXCR4 S347fs*
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: C3 – Early Trials
MYD88 L265P + CXCR4 mutation
Waldenstrom Macroglobulinemia
venetoclax
Resistant: C3 – Early Trials
MYD88 L265P
Waldenstrom Macroglobulinemia
venetoclax
Sensitive: C3 – Early Trials
CD38 expression
Waldenstrom Macroglobulinemia
daratumumab
Sensitive: C3 – Early Trials
MYD88 L265P
Waldenstrom Macroglobulinemia
daratumumab
Sensitive: C3 – Early Trials
CXCR4 mutation
Waldenstrom Macroglobulinemia
daratumumab
Sensitive: C3 – Early Trials
CXCR4 mutation
Waldenstrom Macroglobulinemia
ibrutinib + X4P-001
Sensitive: C3 – Early Trials
MYD88 L265P
Waldenstrom Macroglobulinemia
X4P-001
Sensitive: C3 – Early Trials
CXCR4 mutation
Waldenstrom Macroglobulinemia
ibrutinib + BMS-936564
Sensitive: C3 – Early Trials
MYD88 mutation
Waldenstrom Macroglobulinemia
rituximab
Sensitive: C4 – Case Studies